Fig. 5.

Immunotherapy efficacy improvement via m6A-mediated ferroptosis. The immunosuppressive TME is the primary barrier to effective immunotherapy. The involvement of m6A modification in regulating immune checkpoints and immune cells has been highlighted. On the one hand, RNA m6A modification could influence immune responses by regulating the expression of immune checkpoints such as PD1 and PD-L1. On the other hand, RNA m6A modification could directly affect the functional activities of immune cells, thus modulating immune responses. Therefore, regulating m6A-mediated ferroptosis could enhance the efficacy of immunotherapy to some extent. This figure was created with BioRender.com